Somnos Clinical Research

1. AstraZeneca Pharmaceuticals LP $724,707 38 payments
2. Novartis Pharmaceuticals Corporation $183,136 9 payments
3. AstraZeneca UK Limited $176,371 19 payments
4. Vertex Pharmaceuticals Incorporated $165,281 1 payment
5. CSL Behring $161,849 52 payments
6. Amgen Inc. $144,691 12 payments
7. Adamas Pharmaceuticals, Inc. $100,361 43 payments
8. Amylyx Pharmaceuticals, Inc. $37,886 9 payments
9. Regeneron Pharmaceuticals, Inc. $35,565 23 payments
10. Merck Sharp & Dohme Corporation $33,495 2 payments

1. A Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA) $221,527 7 payments
2. A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) $165,281 1 payment
3. A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis $157,599 50 payments
4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihi $141,821 2 payments
5. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $136,384 10 payments
6. A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) $120,001 2 payments
7. The CHRONICLE Study is a multi center non interventional prospective cohort study of adults with severe asthma who do not achieve control with high dose inhaled corticosteroid ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibody therapy $89,854 4 payments
8. A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study to Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment $78,848 33 payments
9. a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA $63,297 3 payments
10. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $61,905 4 payments

1. Other $5,500 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.